

AMENDMENT UNDER 37 C.F.R. §1.116
U.S. Appln. No. 09/767,943

APPENDIX

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE CLAIMS:

Claim 70 is deleted.

The claims 71-73, 80, 82, 83 and 85 are amended as follows:

Claim 71 (amended). The process according to claim [70] 73, wherein said non-human animal is a mammal.

Claim 72 (amended). The process according to claim [71] 73, wherein said mammal is selected from the group consisting of cows, sheep, horses, pigs, goats, rabbits, dogs, and cats.

Claim 73 (twice amended). [The] A process [according to claim 70] for treating an eye, comprising:

topically applying an azalide antibiotic to an eye of a non-human animal in an amount effective to treat infection in a tissue of the eye, wherein said topically applying comprises supplying a depot of a composition containing said azalide antibiotic on the eye.


Claim 80 (twice amended). The process according to claim [70] 73, wherein said composition further comprises an additional medicament.

Claim 82 (twice amended). The process according to claim [70] 73, wherein said eye is suffering from at least one condition selected from the group consisting of conjunctivitis, ophthalmic neonatorum, trachoma, corneal ulcers, keratitis,

AMENDMENT UNDER 37 C.F.R. §1.116
U.S. Appln. No. 09/767,943

keratoconjunctivitis, endophthalmitis, infectious uveitis and combinations thereof, and said amount of said azalide antibiotic is therapeutically effective to treat said condition.

Claim 83 (Three times Amended). The process according to claim [70] 73, wherein said azalide antibiotic is a compound of formula (I):



(I)

wherein R1 and R2 each independently represent a hydrogen atom or methyl group.

Claim 85 (twice amended). The process according to claim [70] 73, wherein said applying provides a therapeutically effective concentration of azalide antibiotic within a tissue of the eye for at least 8 hours.